Animals with longer gestation times may have fewer cancers, but the way traits relate to cancer risk is complex. Cancer occurs in animals as well as in humans, at widely varying rates among different...
The FDA approved the claudin 18.2-targeted therapy Zolbetuximab-clzb for some gastric and gastroesophageal junction cancers. The U.S. Food and Drug Administration (FDA) has approved zolbetuximab-clzb (Vyloy) plus a chemotherapy regimen consisting of fluoropyrimidine- and platinum-containing...
Immunotherapy lowers risk of side effects in advanced lymphoma, and an extra course of chemotherapy improves survival in cervical cancer.
Treating seemingly inoperable liver tumors with neoadjuvant immunotherapy may make surgery more feasible.
Changes to sexual health during breast cancer treatment can impact quality of life and treatment adherence—especially in Black women.
Expanded dependent coverage improves cancer outcomes in young adults, and breast cancer treatment can lead to faster cell aging.
The PI3K inhibitor is approved as part of combination therapy for certain patients whose breast cancer recurred on or after endocrine therapy. The U.S. Food and Drug Administration (FDA) approved inavolisib (Itovebi), in combination...
Study finds people who receive brain radiation often recover cognitive abilities over time, and report details breast cancer trends.
The immunotherapy is now approved to treat certain lung cancers before and after surgery. The U.S. Food and Drug Administration (FDA) has approved neoadjuvant nivolumab (Opdivo) with platinum-containing chemotherapy, followed by adjuvant nivolumab alone,...
Several recent studies, including on presented at the AACR Conference on the Science of Cancer Health Disparities, have examined the ACA's impact on access to cancer care.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More